In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Semi-Public Utility?

Executive Summary

In most industries, creating strong demand for products is the key to proprietary value--and the more demand, the greater the value. But in the case of both drug and Internet companies this past year, the very thing that should have created enormous value--the potential for extremely wide-scale adoption of their products--instead fostered push back when adoption threatened to become too widespread because it was too valuable for any one company to have on an exclusive basis. The tremendous importance that both pharmaceuticals and the Internet, for different reasons, have assumed in people's lives has turned what should be a proprietary asset into something closer to a semi-public utility.
Advertisement

Related Content

For Dot-Coms, First Mover Disadvantage

Topics

Advertisement
UsernamePublicRestriction

Register

IV001336

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel